{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:50:02Z","timestamp":1760986202257},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00292-023-01183-8","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T10:02:42Z","timestamp":1677232962000},"page":"139-148","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neue WHO-Klassifikation 2022: Harnblasenkarzinom"],"prefix":"10.1007","volume":"44","author":[{"given":"Nadine Therese","family":"Gaisa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Kn\u00fcchel-Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"1183_CR1","unstructured":"WHO Classification of Tumours Editorial Board (2022) Urinary and male genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer. https:\/\/tumourclassification.iarc.who.int\/chapters\/36. Zugegriffen: 7. Juli 2022 (WHO classification of tumours series, 5th ed.; vol. 8)"},{"issue":"2","key":"1183_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.euf.2021.03.017","volume":"8","author":"T van der Kwast","year":"2022","unstructured":"van der Kwast\u00a0T, Liedberg\u00a0F, Black\u00a0PC, Kamat\u00a0A, van Rhijn\u00a0BWG, Algaba\u00a0F, Berman\u00a0DM, Hartmann\u00a0A, Lopez-Beltran\u00a0A, Samaratunga\u00a0H, Varma\u00a0M, Cheng\u00a0L (2022) International society of urological pathology expert opinion on grading of urothelial carcinoma. Eur Urol Focus 8(2):438\u2013446. https:\/\/doi.org\/10.1016\/j.euf.2021.03.017","journal-title":"Eur Urol Focus"},{"key":"1183_CR3","unstructured":"https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/032-038OLl_S3_Harnblasenkarzinom_2020-04-verlaengert.pdf. Zugegriffen: 17. Juli 2022"},{"issue":"4","key":"1183_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1365-2559.2011.03989.x","volume":"59","author":"S Bertz","year":"2011","unstructured":"Bertz\u00a0S, Denzinger\u00a0S, Otto\u00a0W, Wieland\u00a0WF, Stoehr\u00a0R, Hofstaedter\u00a0F, Hartmann\u00a0A (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer\u2014evaluation of a\u00a0large hospital-based single-centre series. Histopathology 59(4):722\u2013732. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03989.x","journal-title":"Histopathology"},{"issue":"1","key":"1183_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0022-5347(17)50167-6","volume":"131","author":"CA Sheldon","year":"1984","unstructured":"Sheldon\u00a0CA, Clayman\u00a0RV, Gonzalez\u00a0R, Williams\u00a0RD, Fraley\u00a0EE (1984) Malignant urachal lesions. J\u00a0Urol 131(1):1\u20138. https:\/\/doi.org\/10.1016\/s0022-5347(17)50167-6","journal-title":"J Urol"},{"key":"1183_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13000-014-0222-8","volume":"9","author":"H Zhong","year":"2014","unstructured":"Zhong\u00a0H, Saby\u00a0G, Kauffman\u00a0E, Guru\u00a0K, Azabdaftari\u00a0G, Xu\u00a0B (2014) Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder\u2014a\u00a0study of 22\u00a0cases from a\u00a0single cancer center. Diagn Pathol 9:222. https:\/\/doi.org\/10.1186\/s13000-014-0222-8","journal-title":"Diagn Pathol"},{"issue":"11","key":"1183_CR7","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/PAS.0000000000001108","volume":"42","author":"AC Tregnago","year":"2018","unstructured":"Tregnago\u00a0AC, Epstein\u00a0JI (2018) Skene\u2019s gland adenokarcinoma: a series of 4 cases. Am J Surg Pathol 42(11):1513\u20131521. https:\/\/doi.org\/10.1097\/PAS.0000000000001108","journal-title":"Am J Surg Pathol"},{"key":"1183_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22864-8","volume-title":"The Paris system for reporting urinary cytology","author":"DL Rosenthal","year":"2016","unstructured":"Rosenthal\u00a0DL, Wojcik\u00a0EM, Kurtycz\u00a0DFI (2016) The Paris system for reporting urinary cytology. Springer, New York"},{"issue":"10","key":"1183_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/PAS.0b013e318042d596","volume":"31","author":"DE Hansel","year":"2007","unstructured":"Hansel\u00a0DE, Epstein\u00a0JI, Berbescu\u00a0E, Fine\u00a0SW, Young\u00a0RH, Cheville\u00a0JC (2007) Renal carcinoid tumor: a\u00a0clinicopathologic study of 21\u00a0cases. Am J Surg Pathol 31(10):1539\u20131544. https:\/\/doi.org\/10.1097\/PAS.0b013e318042d596","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1183_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13000-019-0791-7","volume":"14","author":"B Kim","year":"2019","unstructured":"Kim\u00a0B, Kim\u00a0H\u2011S, Moon\u00a0KC (2019) Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki67 index and mitosis. Diagn Pathol 14(1):12. https:\/\/doi.org\/10.1186\/s13000-019-0791-7","journal-title":"Diagn Pathol"},{"issue":"1","key":"1183_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2559.2004.01980.x","volume":"46","author":"NA Abrahams","year":"2005","unstructured":"Abrahams\u00a0NA, Moran\u00a0C, Reyes\u00a0AO, Siefker-Radtke\u00a0A, Ayala\u00a0AG (2005) Small cell carcinoma oft he bladder: a\u00a0contemporary clinicopathological study of 51\u00a0cases. Histopathology 46(1):57\u201363. https:\/\/doi.org\/10.1111\/j.1365-2559.2004.01980.x","journal-title":"Histopathology"},{"issue":"1","key":"1183_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/JU.0000000000001325","volume":"205","author":"A Hajiran","year":"2021","unstructured":"Hajiran\u00a0A, Azizi\u00a0M, Aydin\u00a0AM, Zemp\u00a0L, Peyton\u00a0CC, Dhillon\u00a0J, Nealon\u00a0S, Reich\u00a0RR, Cao\u00a0B, Li\u00a0R, Manley\u00a0BL, Sexton\u00a0WJ, Gilbert\u00a0SM (2021) Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy. J\u00a0Urol 205(1):100\u2013108. https:\/\/doi.org\/10.1097\/JU.0000000000001325","journal-title":"J Urol"},{"issue":"19","key":"1183_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HPH Neumann","year":"2002","unstructured":"Neumann\u00a0HPH, Bausch\u00a0B, McWhinney\u00a0SR, Bender\u00a0BU, Gimm\u00a0O, Franke\u00a0G, Schipper\u00a0J, Klisch\u00a0J, Altehoefer\u00a0C, Zerres\u00a0K, Januszewicz\u00a0A, Eng\u00a0C, Smith\u00a0WM, Munk\u00a0R, Manz\u00a0T, Glaesker\u00a0S, Apel\u00a0TW, Treier\u00a0M, Reineke\u00a0M, Walz\u00a0MK, Hoang-Vu\u00a0C, Brauckhoff\u00a0M, Klein-Franke\u00a0A, Klose\u00a0P, Schmidt\u00a0H, Maier-Woelfle\u00a0M, Pe\u00e7zkowska\u00a0M, Szmigielski\u00a0C, Eng\u00a0C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N\u00a0Engl J Med 346(19):1459\u20131466. https:\/\/doi.org\/10.1056\/NEJMoa020152","journal-title":"N Engl J Med"},{"key":"1183_CR14","doi-asserted-by":"publisher","unstructured":"van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EMCA, Sleddens HFBM, Derkx P, Rivi\u00e8re J, Dannenberg H, Petri B\u2011J, Komminoth P, Pacak K, Hop WCJ, Pollard PJ, Mannelli M, Bayley J\u2011P, Perren A, Niemann S, Verhofstad AV, de Bru\u00efne AP, Eamonn R Maher ER, Tissier F, M\u00e9atchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, Fran\u00e7ois J, de Herder WW, Vrancken Peeters M\u2011P FM, van Linge A, Lenders JWM, Gimenez-Roqueplo A\u2011P, de Krijger RR, Dinjens WNM. (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a\u00a0retrospective and prospective analysis. Lancet Oncol 10(8):764\u201371 DOI https:\/\/doi.org\/10.1016\/S1470-2045(09)70164-0.","DOI":"10.1016\/S1470-2045(09)70164-0"},{"issue":"9","key":"1183_CR15","doi-asserted-by":"publisher","first-page":"E1472","DOI":"10.1210\/jc.2011-1043","volume":"96","author":"E Korpershoek","year":"2011","unstructured":"Korpershoek\u00a0E, Favier\u00a0J, Gaal\u00a0J, Burnichon\u00a0N, van Gessel\u00a0B, Lindsey Oudijk\u00a0L, Badoual\u00a0C, Gadessaud\u00a0N, Venisse\u00a0A, Bayley\u00a0J\u2011P, van Dooren\u00a0MF, de Herder\u00a0WW, Tissier\u00a0T, Plouin\u00a0P\u2011F, van Nederveen\u00a0FH, Dinjens\u00a0WNM, Gimenez-Roqueplo\u00a0A\u2011P, de Krijger\u00a0RR (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J\u00a0Clin Endocrinol Metab 96(9):E1472\u2013E1476. https:\/\/doi.org\/10.1210\/jc.2011-1043","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1183_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/PAS.0000000000000305","volume":"39","author":"M Zhong","year":"2015","unstructured":"Zhong\u00a0M, Tian\u00a0W, Zhuge\u00a0J, Zheng\u00a0X, Huang\u00a0T, Cai\u00a0D, Zhang\u00a0D, Yang\u00a0XJ, Argani\u00a0P, Fallon\u00a0JT, Epstein\u00a0JI (2015) Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol 39(1):127\u2013131. https:\/\/doi.org\/10.1097\/PAS.0000000000000305","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"1183_CR17","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","volume":"24","author":"MT Chang","year":"2018","unstructured":"Chang\u00a0MT, Penson\u00a0A, Desai\u00a0NB, Socci\u00a0ND, Shen\u00a0R, Seshan\u00a0VE, Kundra\u00a0R, Abeshouse\u00a0A, Viale\u00a0A, Cha\u00a0EK, Hao\u00a0X, Reuter\u00a0VE, Rudin\u00a0CM, Bochner\u00a0BH, Rosenberg\u00a0JE, Bajorin\u00a0DF, Schultz\u00a0N, Berger\u00a0MF, Iyer\u00a0G, Solit\u00a0DB, Al-Ahmadie\u00a0HA, Taylor\u00a0BS (2018) Small-cell carcinomas of the bladder and lung are characterized by a\u00a0convergent but distinct pathogenesis. Clin Cancer Res 24(8):1965\u20131973. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2655","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1183_CR18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.euf.2017.03.007","volume":"4","author":"DS Priemer","year":"2018","unstructured":"Priemer\u00a0DS, Wang\u00a0M, Zhang\u00a0S, Lopez-Beltran\u00a0A, Kouba\u00a0E, Montironi\u00a0R, Davidson\u00a0DD, MacLennan\u00a0GT, Wang\u00a0L, Osunkoya\u00a0AO, Deng\u00a0Y, Emerson\u00a0RE, Cheng\u00a0L (2018) Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common Clonality between small-cell carcinoma of the urinary bladder and Urothelial carcinoma. Eur Urol Focus 4(6):880\u2013888. https:\/\/doi.org\/10.1016\/j.euf.2017.03.007","journal-title":"Eur Urol Focus"},{"key":"1183_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-014-0047-7","volume":"7","author":"X Zheng","year":"2014","unstructured":"Zheng\u00a0X, Zhuge\u00a0J, Bezerra\u00a0SM, Faraj\u00a0SF, Munari\u00a0E, Fallon\u00a0JT 3rd, Yang\u00a0XJ, Argani\u00a0P, Netto\u00a0GJ, Zhong\u00a0M (2014) High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J\u00a0Hematol Oncol 7:47. https:\/\/doi.org\/10.1186\/s13045-014-0047-7","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1183_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot\u00a0Y, Necchi\u00a0A, Park\u00a0SH, Garcia-Donas\u00a0J, Huddart\u00a0R, Burgess\u00a0E, Fleming\u00a0M, Rezazadeh\u00a0A, Mellado\u00a0B, Varlamov\u00a0S, Joshi\u00a0M, Duran\u00a0I, Tagawa\u00a0ST, Zakharia\u00a0Y, Zhong\u00a0B, Stuyckens\u00a0K, Santiago-Walker\u00a0A, De Porre\u00a0P, O\u2019Hagan\u00a0A, Avadhani\u00a0A, Siefker-Radtke\u00a0AO, BLC2001 Study Group. (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 381(4):338\u2013348. https:\/\/doi.org\/10.1056\/NEJMoa1817323","journal-title":"N Engl J Med"},{"issue":"10","key":"1183_CR21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen\u00a0EM, Mouw\u00a0KW, Kim\u00a0P, Iyer\u00a0G, Wagle\u00a0N, Al-Ahmadie\u00a0H, Zhu\u00a0C, Ostrovnaya\u00a0I, Kryukov\u00a0GV, O\u2019Connor\u00a0KW, Sfakianos\u00a0J, Garcia-Grossman\u00a0I, Kim\u00a0J, Guancial\u00a0EA, Bambury\u00a0R, Bahl\u00a0S, Gupta\u00a0N, Farlow\u00a0D, Qu\u00a0A, Signoretti\u00a0S, Barletta\u00a0JA, Reuter\u00a0V, Boehm\u00a0J, Lawrence\u00a0M, Getz\u00a0G, Kantoff\u00a0P, Bochner\u00a0BH, Choueiri\u00a0TK, Bajorin\u00a0DF, Solit\u00a0DB, Gabriel\u00a0S, D\u2019Andrea\u00a0A, Garraway\u00a0LA, Rosenberg\u00a0JE (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140\u20131153. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0623","journal-title":"Cancer Discov"},{"issue":"19","key":"1183_CR22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","volume":"36","author":"G Iyer","year":"2018","unstructured":"Iyer\u00a0G, Balar\u00a0AV, Milowsky\u00a0MI, Bochner\u00a0BH, Dalbagni\u00a0G, Donat\u00a0SM, Herr\u00a0HW, Huang\u00a0WC, Taneja\u00a0SS, Woods\u00a0M, Ostrovnaya\u00a0I, Al-Ahmadie\u00a0H, Arcila\u00a0ME, Riches\u00a0JC, Meier\u00a0A, Bourque\u00a0C, Shady\u00a0M, Won\u00a0H, Rose\u00a0TL, Kim\u00a0WY, Kania\u00a0BE, Boyd\u00a0ME, Cipolla\u00a0CK, Regazzi\u00a0AM, Delbeau\u00a0D, McCoy\u00a0AS, Vargas\u00a0HA, Berger\u00a0MF, Solit\u00a0DB, Rosenberg\u00a0JE, Bajorin\u00a0DF (2018) Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J\u00a0Clin Oncol 36(19):1949\u20131956. https:\/\/doi.org\/10.1200\/JCO.2017.75.0158","journal-title":"J Clin Oncol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-023-01183-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:04:58Z","timestamp":1678287898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-023-01183-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1007\/s00292-023-01183-8","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"22 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>N.T.\u00a0Gaisa:<\/b> A.\u00a0Finanzielle Interessen: Forschungsunterst\u00fctzung im Rahmen einer Studie von Janssen-Cilag; Honorare f\u00fcr Fortbildungsveranstaltungen von AstraZeneca, Janssen-Cilag, Beyer, Zytomed; Ad-boards f\u00fcr Janssen-Cilag, AstraZeneca.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: aktuell stellvertretende Leitung, sonst Ober\u00e4rztin, Leiterin Lehr- und Forschungsgebiet onkologische Pathologie, Institut f\u00fcr Pathologie Uniklinik RWTH Aachen, Aachen; Mitglied, Deutsche Gesellschaft f\u00fcr Pathologie, Deutsche Krebsgesellschaft, Internationale Akademie f\u00fcr Pathologie, BRIDGE e.\u202fV., DFBK e.\u202fV., IBCN; Sprecherin, Arbeitsgemeinschaft Uropathologie der Deutschen Gesellschaft f\u00fcr Pathologie; Hauptmandatstr\u00e4gerin der AOP in der Zertifizierungskommission der DKG f\u00fcr Harnblasen-, Nieren- und Hodenkrebs. <b>A.\u00a0Hartmann:<\/b> A.\u00a0Finanzielle Interessen: Forschungsunterst\u00fctzung von AstraZeneca, Biontech, Cepheid, Illumina, Janssen, Nanostring, Novartis, Owkin, Qiagen, QUIP GmbH, Roche, Sanofi; Honorare f\u00fcr Vortr\u00e4ge oder Beratung\/Advisory Boards f\u00fcr Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, Sanofi, 3DHistotech und andere.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: seit 16.08.07 Direktor, Pathologisches Institut der Universit\u00e4t Erlangen-N\u00fcrnberg; Mitglied Vorstand des CCC Erlangen-EMN seit 2010; Mitglied Vorstand und Koordinator Nachwuchsf\u00f6rderung, Deutsche Gesellschaft f\u00fcr Pathologie 2011\u20132018; Mitglied Fachkollegium Medizin der DFG, Sektion\u00a02 \u201eKrebsforschung und Regenerative Medizin\/Stammzellforschung seit 2012\u20132020, Vorsitzender Sektion\u00a02 2016\u20132020; Mitglied Vorstand und Programmkommission der Deutschen Sektion der Internationalen Akademie f\u00fcr Pathologie seit 2012; Pr\u00e4sident der Deutschen Sektion der Internationalen Akademie f\u00fcr Pathologie 2019\u20132021; Mitglied Sektorkomitee Pathologie\/Neuropathologie der Deutschen Akkreditierungstelle (DAkkS) seit 2014, Vorsitzender des Sektorkomitees seit 2018; Board Member, Working Group Uropathology, European Society of Pathology seit 2011; Mitglied der Leopoldina 2022. <b>R.\u00a0Kn\u00fcchel-Clarke:<\/b> A.\u00a0Finanzielle Interessen: DFG-Sachmittel und Personal im Rahmen von Graduiertenkolleg und Klinischer Studie; Referent AUO Fortbildung reine Kostenerstattung; DFG-Fachkollegium als Fachkollegiat reine Kostenerstattung; Krebshilfe-Nachwuchsausschuss als Mitglied reine Kostenerstattung; Wissenschaftlicher Beirat LKR NRW als Mitglied reine Kostenerstattung; IAP-Seminar als Referent reine Kostenerstattung.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Emeritierte Universit\u00e4tsprofessorin Uniklinik RWTH Aachen; Gastwissenschaftlerin als Universit\u00e4tsprofessorin Uniklinik RWTH Aachen; IAP\u00a0\u2013 Mitglied; DGP\u00a0\u2013 Mitglied; BVPathologie\u00a0\u2013 Mitglied; DFG-Fachkollegiat; S3-Leitlinie Harnblasenkarzinom\u00a0\u2013 Mitglied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}